Anaveon appoints Dr Eduard Gasal as Chief Medical Officer

Written by: Editor
Published on: 5 Dec 2022

Appointment [square]An experienced CMO with a track record of multiple filings and drug approvals

Basel, November 30, 2022 – Anaveon, a clinical stage, immuno-oncology company, today announced the appointment of Dr Eduard Gasal as Chief Medical Officer (CMO). Dr Gasal will follow Dr Christoph Bucher, who is stepping down to increase his time practising clinical hematology. Dr Gasal is a seasoned clinical development professional with strong experience leading global cross-functional teams in oncology, encompassing early and late-stage clinical development for numerous tumor types with multiple regulatory filings and drug approval experience.

“Eduard brings a wealth of experience across all aspects of clinical development, clinical operations and medical affairs, along with exceptional performance in helping to bring several high-profile oncology drugs to market,” said Dr Andreas Katopodis, Chief Executive Officer at Anaveon. “His expertise will be invaluable as we advance our lead candidate ANV419 through development in multiple tumor types and expand our pipeline with novel drug candidates. We are grateful to Christoph for his scientific, operational, and strategic leadership of successfully bringing ANV419 to the clinic.”

Dr Eduard Gasal commented on his appointment, “I am delighted to join Anaveon to lead the clinical development program. ANV419’s differentiated profile is exciting and allows the delivery of high dose IL-2 to patients with a tolerable safety profile. I look forward to working with the Anaveon team to advance the existing development program to the next stage whilst broadening the pipeline with new programs and in new indications.”

Dr Gasal previously served as President of Innovent Biologics (USA), Inc. where he was responsible for the clinical development strategy and execution outside of China. Prior to that he was Executive Director and Global Program Clinical Head at Novartis leading the cross functional clinical team for the melanoma and prostate cancer franchise with main accountability for a large clinical development program consisting of more than 25 clinical studies (Phase I to Phase III) with targeted therapies. Previously he served in roles of increasing responsibility at Amgen and Roche. Dr Gasal received his Master’s Degree and Medical Doctor Degree in Human Medicine from the University of Zurich in Switzerland.